Results 11 to 20 of about 57,027 (223)

Correction to "Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup-specific prognostic stratification using economical/accessible diagnostic methods". [PDF]

Brain Pathol
Brain Pathology, EarlyView.
europepmc   +4 more sources

Modeling pediatric medulloblastoma [PDF]

Brain Pathology, 2019
AbstractMouse models of medulloblastoma have proven to be instrumental in understanding disease mechanisms, particularly the role of epigenetic and molecular drivers, and establishing appropriate preclinical pipelines. To date, our research community has developed murine models for all four groups of medulloblastoma, each of which will be critical for ...
Roussel, Martine F., Stripay, Jennifer L.   +1 more
openaire   +3 more sources

Is there a role for immune checkpoint inhibitors in high-risk medulloblastoma beyond the salvage setting? [PDF]

Oncologist
Wang YL, Wu CT, Kao WH, Chang TY, Jaing TH.   +4 more
europepmc   +3 more sources

Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency. [PDF]

Nat Genet
Tao R, Erkek-Ozhan S, Xu B, Matsui Y, Mittal P, Smith KS, Li Y, Filipovic D, Xu R, Gao Q, Darrow E, Kumar R, Djekidel N, Bajpai R, Hadley J, Batts M, Lewis SA, Soliman T, Reilly C, Bhanu NV, Paul L, Lin H, Gudenas B, Lowe K, Zapatka M, Sieber L, Jones DTW, Kool M, Waszak SM, Hovestadt V, Buchhalter I, Ryzhova M, Korshunov A, Lichter P, Chavez L, Kutscher LM, Garcia BA, Pruett-Miller SM, Zhou X, Orr BA, Robinson GW, Wu G, Korbel JO, Peng JC, Pfister SM, Northcott PA.   +45 more
europepmc   +3 more sources

In Reply: Immune checkpoint inhibition in medulloblastoma: moving toward biologically informed strategies. [PDF]

Oncologist
Viana-Pereira M, Fontão P, Reis RM.
europepmc   +2 more sources

Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity With High-Density Progenitor Cell Regions Correlating With High-Risk Disease. [PDF]

JCO Precis Oncol
Chien F, Michaud ME, Bakhtiari M, Schroff C, Snuderl M, Velazquez Vega JE, MacDonald TJ, Bhasin MK.   +7 more
europepmc   +3 more sources

Paediatric therapeutic development workshop on medulloblastoma. [PDF]

Br J Cancer
\ua9 The Author(s) 2026. The second Paediatric Therapeutic Development Workshop focused on medulloblastoma. Between 60–70% of patients with medulloblastoma survive, but survivors have significant long-term side effects, and the highest-risk groups have a
Montiel Equihua C, Baxter JS, Molenaar JJ, Areso I, Abbou S, Anderson J, Andre N, Ayrault O, Blanc P, Carpenter N, Daems S, D'Angiolella V, Danielson L, Donovan L, Durbin AD, Fouladi M, Gajjar A, Gilbertson R, Giraud G, Gottardo N, Hill R, Kearns P, Kool M, Lass G, Marino S, Mueller S, Newman S, Olson J, Patel S, Pfister SM, Rainsbury J, Ramaswamy V, Rutkowski S, Straathof K, Swartling FJ, Wechsler-Reya RJ, Pearson ADJ, Jenkinson D, Doz F, Clifford SC, LifeArc, Innovative Therapies for Children with Cancer (ITCC), Cancer Research UK, Cancer Grand Challenge Protect team.   +43 more
europepmc   +4 more sources

A Rare Instance of Adult Medulloblastoma Presenting Imaging Heterogeneity Correlating With Molecular Subtypes and Anatomical Locations. [PDF]

Clin Case Rep
Wang Z, Guan C, Zhang J, Wu J, Chen Y, Feng Y, Cui Z, Shen C, Guo P.   +8 more
europepmc   +3 more sources

Molecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival. [PDF]

Brain Pathol
A practical formalin‐fixed, paraffin‐embedded (FFPE)‐based molecular workflow integrating pathology, immunohistochemistry, and genomic profiling provides clinically meaningful subgroup classification of pediatric medulloblastoma and expands molecular evidence from an underrepresented Central Asian population. Abstract Medulloblastoma is the most common
Bolatov A, Zhakupov A, Abdikadirova A, Sapargaliyeva M, Ibraimov B, Zhalimbetova Z, Ólenbay G, Zhetpisbayev B, Xu X, Bayanova M.   +9 more
europepmc   +2 more sources

Medulloblastoma-associated mutations in the RNA helicase DDX3X/DED1 cause defects in the translational response to TORC1 inhibition. [PDF]

J Biol Chem
Swarup A, Kuhs RA, Hardman VU, Howard KL, Subbaraman S, Bolger TA.   +5 more
europepmc   +2 more sources